Lakewood-amedex Biotherapeutics INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Lakewood-Amedex Biotherapeutics has filed an S-1/A registration statement for a direct listing on the Nasdaq Capital Market.
NASDAQ
Lakewood-Amedex Biotherapeutics Inc. is pursuing a direct listing on the Nasdaq Capital Market and a $7.5 million Series C Preferred Stock financing to advance its antimicrobial pipeline, despite ongoing significant losses and a going concern warning.
NASDAQ
Lakewood-Amedex Biotherapeutics seeks a Nasdaq direct listing with a concurrent $7.5m Series C preferred financing and aims to start a Phase 2a trial for lead anti-infective Nu-3.